Amicus Therapeutics (FOLD) Shares Down 5.2%

Share on StockTwits

Amicus Therapeutics, Inc. (NASDAQ:FOLD) fell 5.2% on Monday . The company traded as low as $12.02 and last traded at $12.07. 2,496,029 shares traded hands during trading, a decline of 19% from the average session volume of 3,063,584 shares. The stock had previously closed at $12.73.

A number of research firms have weighed in on FOLD. Zacks Investment Research upgraded Amicus Therapeutics from a “sell” rating to a “hold” rating in a research report on Wednesday, January 23rd. Cantor Fitzgerald set a $20.00 price target on Amicus Therapeutics and gave the company a “buy” rating in a research report on Wednesday, May 8th. BidaskClub upgraded Amicus Therapeutics from a “sell” rating to a “hold” rating in a research report on Monday, February 25th. Janney Montgomery Scott began coverage on Amicus Therapeutics in a research report on Friday, April 5th. They set a “buy” rating and a $13.91 price target on the stock. Finally, ValuEngine downgraded Amicus Therapeutics from a “buy” rating to a “hold” rating in a research report on Tuesday, February 5th. Three equities research analysts have rated the stock with a hold rating and seven have assigned a buy rating to the company’s stock. Amicus Therapeutics has a consensus rating of “Buy” and an average price target of $18.19.

The firm has a market capitalization of $2.86 billion, a P/E ratio of -9.41 and a beta of 1.79. The company has a debt-to-equity ratio of 0.45, a current ratio of 7.33 and a quick ratio of 7.21.

Amicus Therapeutics (NASDAQ:FOLD) last released its quarterly earnings data on Wednesday, May 8th. The biopharmaceutical company reported ($0.39) EPS for the quarter, missing the Thomson Reuters’ consensus estimate of ($0.30) by ($0.09). The company had revenue of $34.00 million during the quarter, compared to analysts’ expectations of $37.82 million. Amicus Therapeutics had a negative return on equity of 64.11% and a negative net margin of 386.18%. The company’s quarterly revenue was up 103.6% compared to the same quarter last year. As a group, analysts expect that Amicus Therapeutics, Inc. will post -1.32 earnings per share for the current fiscal year.

In related news, CEO John F. Crowley sold 20,000 shares of the firm’s stock in a transaction dated Friday, March 1st. The stock was sold at an average price of $13.60, for a total value of $272,000.00. Following the sale, the chief executive officer now directly owns 678,844 shares of the company’s stock, valued at $9,232,278.40. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which can be accessed through the SEC website. Also, insider Jay Barth sold 70,000 shares of the firm’s stock in a transaction dated Monday, February 25th. The stock was sold at an average price of $12.52, for a total value of $876,400.00. Following the completion of the sale, the insider now directly owns 156,037 shares in the company, valued at $1,953,583.24. The disclosure for this sale can be found here. In the last quarter, insiders sold 180,000 shares of company stock worth $2,401,200. Company insiders own 2.90% of the company’s stock.

Hedge funds and other institutional investors have recently bought and sold shares of the stock. Dimensional Fund Advisors LP grew its stake in shares of Amicus Therapeutics by 374.8% in the fourth quarter. Dimensional Fund Advisors LP now owns 1,098,083 shares of the biopharmaceutical company’s stock worth $10,518,000 after purchasing an additional 866,793 shares during the last quarter. Vanguard Group Inc. grew its stake in shares of Amicus Therapeutics by 3.3% in the third quarter. Vanguard Group Inc. now owns 16,807,772 shares of the biopharmaceutical company’s stock worth $203,205,000 after purchasing an additional 541,308 shares during the last quarter. Sofinnova Investments Inc. grew its stake in shares of Amicus Therapeutics by 51.3% in the fourth quarter. Sofinnova Investments Inc. now owns 674,636 shares of the biopharmaceutical company’s stock worth $6,462,000 after purchasing an additional 228,667 shares during the last quarter. Xact Kapitalforvaltning AB grew its stake in shares of Amicus Therapeutics by 15.7% in the fourth quarter. Xact Kapitalforvaltning AB now owns 33,841 shares of the biopharmaceutical company’s stock worth $324,000 after purchasing an additional 4,600 shares during the last quarter. Finally, Emory University grew its stake in shares of Amicus Therapeutics by 7.5% in the fourth quarter. Emory University now owns 217,874 shares of the biopharmaceutical company’s stock worth $2,087,000 after purchasing an additional 15,148 shares during the last quarter.

COPYRIGHT VIOLATION WARNING: This report was first reported by Week Herald and is the sole property of of Week Herald. If you are reading this report on another publication, it was illegally copied and reposted in violation of United States and international copyright laws. The original version of this report can be viewed at https://weekherald.com/2019/05/15/amicus-therapeutics-fold-shares-down-5-2.html.

Amicus Therapeutics Company Profile (NASDAQ:FOLD)

Amicus Therapeutics, Inc, a biotechnology company, engages in the discovery, development, and commercialization of medicines for various rare and orphan diseases. The company offers Galafold, an orally administered small molecule pharmacological chaperone for the treatment of Fabry disease. It is also conducting a Phase 1/2 clinical study of ATB200-02 for indications, including pompe disease.

Further Reading: Federal Reserve

Receive News & Ratings for Amicus Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Amicus Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.